Nuvectis Pharma (NVCT) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed ProKidney (PROK) over the past year, gaining 232.1% versus a loss of 47.0%. ProKidney is the larger company by market cap ($654.7 million vs $650.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | PROK |
|---|---|---|
| Share price | $19.93 | $1.64 |
| Market cap | $650.60M | $654.66M |
| 1-day change | -1.77% | +4.46% |
| YTD return | +168.74% | -29.91% |
| 1-year return | +232.08% | -46.96% |
| 5-year return | — | -84.09% |
| EPS (TTM) | $-1.31 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $3.48 |
| 52-week low | $5.55 | $1.30 |
| Distance from 52-week high | -31.92% | -52.87% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +77.62% | +281.10% |
| Average volume | 217.91K | 1.30M |
| Shares outstanding | 32.64M | 208.93M |
| Employees | 16 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed PROK by 279.0 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
NVCT vs PROK FAQ
Which is bigger, Nuvectis Pharma or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $654.66M compared with $650.60M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, NVCT or PROK?
NVCT returned +232.08% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and ProKidney in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Nuvectis Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for ProKidney.